The retinal biologics market was valued at $14.9 billion in 2022 and is projected to reach $24.7 billion by 2032,registering a CAGR of 5.1% from 2023 to 2032. Retinal biologics is a class of medications or therapies that are designed to treat various retinal diseases and conditions. These biologics are specifically developed to target the retina, which is the light-sensitive tissue lining the inner surface of the eye. Retina-related diseases such as age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion are often managed through intravitreal injections of biologic drugs. These biologics are typically monoclonal antibodies or other proteins that target specific molecules involved in the disease process. They may help
reduce inflammation, prevent abnormal blood vessel growth, or promote the growth of healthy blood vessels in the retina by targeting these molecules.
One of the most well-known biologics used in the treatment of retinal conditions is Ranibizumab (brand name Lucentis), which is used for age-related macular degeneration and macular edema. Another commonly used biologic is aflibercept (brand name Eylea), which targets AMD age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Bevacizumab (brand name Avastin), although primarily approved for cancer treatment, is sometimes used off-label in ophthalmology for similar indications.
The retina biologics market has experienced significant growth owing to rise in prevalence of retinal diseases, rise in geriatric population suffering from retinal disorders diseases, and advancements in biotechnology and ophthalmic research. For instance, according to the (NCBI) in 2020, approximately 196 million people worldwide to affected by AMD, with a global prevalence of 8.69%. In addition, Increase in awareness among patients and healthcare professionals about the efficacy and benefits of biologic therapies drive the market growth.
Furthermore, ongoing research and development activities in the field of retinal biologics contribute to market growth. Pharmaceutical companies, academic institutions, and research organizations invest in discovering and developing innovative therapies, improving treatment efficacy, and expanding the range of available retinal biologics. For instance, Atsena Therapeutics Inc. conducting a clinical trial to evaluate the safety and tolerability of ATSN-201 in male subjects 6 to 64 years old with RS1-associated X-linked retinoschisis (XLRS).
Moreover, advances in biotechnology, such as genetic engineering, recombinant DNA technology, and targeted drug delivery systems, have revolutionized the field of retinal biologics that support the market growth. These advancements have enabled the development of highly targeted and efficacious therapies that specifically address the underlying mechanisms of retinal diseases, improving treatment outcomes and driving the market growth. However, high cost of retinal drugs may limit the adoption of retinal biologic drugs and restrain the market growth.
The retinal biologics market is segmented into drug class, indication, distribution channel, and region. On the basis of drug class, the market is bifurcated into VEGF-A antagonist and others. The VEGF-A antagonist segment is further categorized into Aflibercept, Ranibizumab, and others. On the basis of indication, the market is categorized into macular degeneration, diabetic retinopathy, and others. On the basis of distribution channel, the market is categorized into hospital pharmacies, drug stores and retail pharmacies, and online providers. On the basis of, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Latin America and Middle East and Africa).
Major key players that operate in the retinal biologics market are AbbVie Inc., Amgen Inc., Bayer AG, Biocon, Biogen, Coherus BioSciences, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Outlook Therapeutics, Inc., and Regeneron Pharmaceuticals, Inc. Key players have adopted product launch, product approval, and collaboration as key developmental strategies to improve the product portfolio of the retinal biologics market.
reduce inflammation, prevent abnormal blood vessel growth, or promote the growth of healthy blood vessels in the retina by targeting these molecules.
One of the most well-known biologics used in the treatment of retinal conditions is Ranibizumab (brand name Lucentis), which is used for age-related macular degeneration and macular edema. Another commonly used biologic is aflibercept (brand name Eylea), which targets AMD age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Bevacizumab (brand name Avastin), although primarily approved for cancer treatment, is sometimes used off-label in ophthalmology for similar indications.
The retina biologics market has experienced significant growth owing to rise in prevalence of retinal diseases, rise in geriatric population suffering from retinal disorders diseases, and advancements in biotechnology and ophthalmic research. For instance, according to the (NCBI) in 2020, approximately 196 million people worldwide to affected by AMD, with a global prevalence of 8.69%. In addition, Increase in awareness among patients and healthcare professionals about the efficacy and benefits of biologic therapies drive the market growth.
Furthermore, ongoing research and development activities in the field of retinal biologics contribute to market growth. Pharmaceutical companies, academic institutions, and research organizations invest in discovering and developing innovative therapies, improving treatment efficacy, and expanding the range of available retinal biologics. For instance, Atsena Therapeutics Inc. conducting a clinical trial to evaluate the safety and tolerability of ATSN-201 in male subjects 6 to 64 years old with RS1-associated X-linked retinoschisis (XLRS).
Moreover, advances in biotechnology, such as genetic engineering, recombinant DNA technology, and targeted drug delivery systems, have revolutionized the field of retinal biologics that support the market growth. These advancements have enabled the development of highly targeted and efficacious therapies that specifically address the underlying mechanisms of retinal diseases, improving treatment outcomes and driving the market growth. However, high cost of retinal drugs may limit the adoption of retinal biologic drugs and restrain the market growth.
The retinal biologics market is segmented into drug class, indication, distribution channel, and region. On the basis of drug class, the market is bifurcated into VEGF-A antagonist and others. The VEGF-A antagonist segment is further categorized into Aflibercept, Ranibizumab, and others. On the basis of indication, the market is categorized into macular degeneration, diabetic retinopathy, and others. On the basis of distribution channel, the market is categorized into hospital pharmacies, drug stores and retail pharmacies, and online providers. On the basis of, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Latin America and Middle East and Africa).
Major key players that operate in the retinal biologics market are AbbVie Inc., Amgen Inc., Bayer AG, Biocon, Biogen, Coherus BioSciences, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Outlook Therapeutics, Inc., and Regeneron Pharmaceuticals, Inc. Key players have adopted product launch, product approval, and collaboration as key developmental strategies to improve the product portfolio of the retinal biologics market.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the retinal biologics market analysis from 2022 to 2032 to identify the prevailing retinal biologics market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the retinal biologics market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report Includes the analysis of the regional as well as global retinal biologics market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Distribution Channel
- Hospital Pharmacies
- Online Providers
- Drug Stores and Retail Pharmacies
By Drug Class
- VEGF-A Antagonist
- Type
- Aflibercept
- Ranibizumab
- Others
- Others
By Indication
- Macular Degeneration
- Diabetic Retinopathy
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Latin America
- Middle East And Africa
Key Market Players
- AbbVie Inc.
- Amgen Inc.
- Bayer AG
- Biocon
- Biogen
- Coherus BioSciences, Inc.
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Outlook Therapeutics, Inc.
- Regeneron Pharmaceuticals, Inc.
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: RETINAL BIOLOGICS MARKET, BY DRUG CLASS
CHAPTER 5: RETINAL BIOLOGICS MARKET, BY INDICATION
CHAPTER 6: RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL
CHAPTER 7: RETINAL BIOLOGICS MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to a new report, titled, 'Retinal Biologics Market,' The retinal biologics market was valued at $14.9 billion in 2022, and is estimated to reach $24.7 billion by 2032, growing at a CAGR of 5.1% from 2023 to 2032.Retinal biologics are medications used to treat several retinal conditions. They are typically administered as injections directly into the eye. They are specifically designed to target and inhibit the activity of a protein called vascular endothelial growth factor (VEGF), which plays a crucial role in promoting the growth of abnormal blood vessels in the retina. The most used retinal biologics include ranibizumab (Lucentis), bevacizumab (Avastin), and aflibercept (Eylea).
Key factors driving the growth of the retinal biologics market include a rise in prevalence of retinal diseases such as age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. The anti-vascular endothelial growth factor (anti-VEGF) agents are the primary treatment for age-related macular degeneration. For instance, according to the National Center for Biotechnology and Information (NCBI), age-related macular degeneration (AMD) was the most common retinal disease (35.43%), hypertensive retinopathy (4.35%), epiretinal membrane (ERM) (3.66%), branch retinal vein occlusion (BRVO) (2.90%), and diabetic retinopathy (DR) (2.15%) in 2020. Thus, the rise in cases of retinal diseases drives the market growth.
In addition, the rise in the geriatric population and it is a significant risk factor for retinal diseases which drive the market growth. There is a higher demand for retinal biologics to address age-related retinal diseases, stimulating market growth. Furthermore, higher awareness about retinal diseases, advancements in diagnostic techniques, and regular eye screenings resulted in early detection and diagnosis of retinal diseases. This led to an increase in the demand for retinal biologics.
Furthermore, retinal biologics offer the advantage of minimally invasive treatments compared to traditional surgical procedures supporting the market growth. They provide targeted therapy and reduce the need for invasive surgeries, leading to faster recovery and improved patient outcomes. Thus, increase in demand for minimally invasive treatments drives the
adoption of retinal biologics drugs. Moreover, favorable government policies contribute to the growth of the market. For instance, National Programme for Control of Blindness and Visual Impairment (NPCB and VI), an Indian Government initiative to reduce the prevalence of avoidable blindness. Such initiatives given by the government drive the market growth.
The market also offers growth opportunities to the key players in the market. Rise in research and development activities in retinal gene therapies and growth opportunities in emerging countries propels the market growth. For instance, Outlook Therapeutics, Inc. is developing a Bevacizumab-vikg a recombinant humanized monoclonal antibody (mAb) for the treatment of retinal diseases. In addition, AbbVie Inc. developing ABBV-RGX-314 a potential one-time gene therapy being investigated for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases. Therefore, an increase in research and development activities provides lucrative opportunity for market growth. Furthermore, increase in awareness about retinal diseases and their treatment in emerging countries also provide opportunity to the growth of the retinal biologics market in these regions.
The retinal biologics market is segmented into drug class, indication, end user, and region. On the basis of type, the market is categorized into VEGF-A antagonist and others. The VEGF-A antagonist segment is further categorized into Aflibercept, Ranibizumab, and others. On the basis of the indication, it is categorized into macular degeneration, diabetic
retinopathy, and others. On the basis of distribution channel, it is fragmented into hospital pharmacies, drug stores and retail pharmacies, and online providers. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, and rest of Asia-Pacific), and LAMEA ((Latin America and Middle East and Africa).
The key players profiled in the study include AbbVie Inc., Amgen Inc., Bayer AG, Biocon, Biogen, Coherus BioSciences, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Outlook Therapeutics, Inc., and Regeneron Pharmaceuticals, Inc. The players in the market have been actively engaged in the adoption of various strategies such as adopted product launch, product approval,
and collaboration to remain competitive and gain an advantage over the competitors in the market. For instance, in September 2021, AbbVie Inc. has announced a collaboration with RegenxBio to develop and market a potential one-time gene therapy, RGX-314, for treating wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases.
Key Market Insights
- By drug class, the VEGF-A antagonist segment was the largest revenue contributor to the market and is estimated to reach $23.4 billion by 2032, with a highest CAGR of 5.2% during forecast period.
- By indication, the macular degeneration segment dominated the global market in 2022. However, the diabetic retinopathy segment is expected to be the fastest-growing segment with a CAGR of 5.5% during the forecast period.
- Based on distribution channel, the hospital pharmacies segment was the largest revenue contributor to the market with the highest CAGR during the forecast period.
- Based on region, North America garnered the largest revenue share in 2022, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Companies Mentioned
- AbbVie Inc.
- Amgen Inc.
- Bayer AG
- Biocon
- Biogen
- Coherus BioSciences, Inc.
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Outlook Therapeutics, Inc.
- Regeneron Pharmaceuticals, Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
